Key terms
About SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SPRY news
Apr 03
9:19am ET
ARS Pharmaceuticals submits response to FDA’s CRL for neffy nasal spray
Mar 24
9:25pm ET
Buy Rating on ARS Pharmaceuticals Amid Strong neffy Approval Prospects and Indication Expansion
Mar 23
2:01am ET
Ars Pharmaceuticals’ Merger May Limit Use of Net Operating Losses, Impacting Future Financials
Mar 21
4:16pm ET
ARS Pharmaceuticals reports FY23 EPS (57c), consensus (14c)
Mar 11
6:45am ET
Neffy’s Market Potential and ARS Pharmaceuticals’ Buy Rating Reinforced by Clinical Success
Mar 07
1:13pm ET
ARS Pharmaceuticals Updates Stakeholders with New Presentation
Mar 07
12:25pm ET
ARS Pharmaceuticals to hold virtual investor day
Mar 07
12:05am ET
ARS Pharmaceuticals to hold virtual investor day
Mar 05
9:45am ET
Lyft upgraded, Philip Morris downgraded: Wall Street’s top analyst calls
Mar 05
6:09am ET
ARS Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
Feb 26
9:04am ET
ARS Pharmaceuticals reports neffy meets primary endpoints in Phase 2 study
Feb 22
12:16am ET
Hold Rating Maintained for ARS Pharmaceuticals Amid FDA Approval Process and Commercialization Concerns
Feb 21
11:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 20
11:32am ET
ARS Pharmaceuticals upgraded to Outperform from Market Perform at William Blair
Feb 20
9:15am ET
ARS Pharmaceuticals announces results from repeat dosing study of neffy
Feb 06
11:05am ET
Buy Rating Affirmed: ARS Pharmaceuticals’ Neffy Shows Promise in Clinical Trials with Strong Market Potential
Feb 05
9:12am ET
ARS Pharmaceuticals to present efficacy data for neffy at 2024 AAAAI meeting
Apr 16
11:15pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 15
3:00am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 11
3:30am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 08
7:30pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
SPRY Financials
Key terms
Ad Feedback
SPRY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SPRY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
